New Product thread from old FGF5 Aptamer posting, page-8

The concept that activity of MK is related to a certain section or sections of the molecule was certainly not new to CDY/Lyramid Pharma.

Claims made in the various antibody patents are specifically directed to particular regions (‘domains’) of the molecule. For example, you will find the following phrases within claims made in various Lyramid patents -

(1) “ .. which is an antibody fragment which binds huMK”;

(2) “ .. fragment or single domain antibody”;

(3) “ .. an antigen binding domain of midkine (MK) as defined by amino acid residues located within the N-domain of midkine (MK) …”;

(4) “An isolated anti-midkine antibody or an antigen-binding fragment thereof ..”;

poorinvestor